Xiao Gutian, Rabson Arnold B, Young Wise, Qing Guoliang, Qu Zhaoxia
Department of Cell Biology and Neuroscience, W.M. Keck Center for Collaborative Neuroscience, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Cytokine Growth Factor Rev. 2006 Aug;17(4):281-93. doi: 10.1016/j.cytogfr.2006.04.005. Epub 2006 Jun 21.
While the classical pathway of NF-kappaB activation plays critical roles in a wide range of biological processes, the more recently described "non-canonical" NF-kappaB pathway has important but more restricted roles in both normal and pathological processes. The non-canonical NF-kappaB pathway, based on processing of the nf-kappab2 gene product p100 to generate p52, appears to be involved in B-cell maturation and lymphoid development. Deregulated activation of this pathway has been observed in a variety of malignant and autoimmune diseases, thus inhibitors that specifically target p100 processing might be predicted to have potential roles as immunomodulators and in the therapy of malignant diseases. We review current understandings of NF-kappaB activation, particularly the mechanisms of p100 processing under both physiological and pathological conditions.
虽然经典的核因子-κB（NF-κB）激活途径在广泛的生物学过程中发挥着关键作用，但最近描述的“非经典”NF-κB途径在正常和病理过程中具有重要但更具局限性的作用。基于nf-κb2基因产物p100的加工以产生p52的非经典NF-κB途径似乎参与B细胞成熟和淋巴细胞发育。在多种恶性和自身免疫性疾病中已观察到该途径的失调激活，因此可以预测，特异性靶向p100加工的抑制剂可能作为免疫调节剂以及在恶性疾病治疗中具有潜在作用。我们综述了目前对NF-κB激活的认识，特别是生理和病理条件下p100加工的机制。
